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We applaud the compilation of
a Special Topic Series of [The Clinical
Journal of Pain (May/June 2005,
Volume 21, Issue 3)] on functional
capacity testing. The issue certainly
contributes to the much-needed body
of knowledge on functional capacity
evaluations (FCEs). In the introduc-
tion of the issue, it was suggested that
the responsiveness of functional tests
be researched.1 Others2,3 have also
suggested this. Recently, we have
attempted to perform responsiveness
research using an existing data set of
the material handling tests of FCE
performances before and after a
rehabilitation program in patients
with nonspeciﬁc chronic low back
pain (CLBP). Diﬀerences in perfor-
mances before and after treatment
were observed (Table 1). However,
during the study we experienced
2 major diﬃculties in our 2 ap-
proaches.
Our ﬁrst approach to the analy-
sis of responsiveness was to compare
the change in FCE results to an
external criterion (gold standard). A
change in FCE performance impli-
cates a change in functional status.
Therefore, external criteria should be
related to the construct functional
status. However, neither self-reports
of function nor actual functioning,
eg, in work, can be used as external
criterion because it has been demon-
strated that performances during
functional testing and self-reported
measures of function are substantially
diﬀerent and weakly to moderately
related.4,5 Similarly, weak relation-
ships exist between FCE performance
and work status.6–8 These ﬁndings
were conﬁrmed in our study. Rela-
tionships between FCE performances
and diﬀerences in pain intensity, in
self-reported disability, and in self-
reported limitations in performing
lifting tasks were weak or insigniﬁcant
(not presented). It appears that a gold
standard is unavailable.
In a second approach to the
analysis of responsiveness, we com-
pared the observed change in perfor-
mance with the ‘‘natural variation’’ in
the measurement. The natural varia-
tion (also known as limits of agree-
ment) may serve as an internal or
statistical criterion to demonstrate
improvement over time. The natural
variation of FCE measurements has
been studied in patients with
CLBP and in healthy patients.9,10
The results of these studies showed
that this natural variation is substan-
tial, eg, in the lifting performance of
patients with CLBP, the limit of
agreement is±19.8 kg.10 This means
that a progress of 19.8 kg in lifting
performance must be observed to
exceed the natural variation of the
measurement. The clinical relevance
of this criterion should therefore be
questioned.
Although diﬀerences in FCE
performances before and after treat-
ment were found (Table 1), we are
unable to determine whether these
diﬀerences represent clinically impor-
tant changes in the observed func-
tional performance because of the
absence of a valid external criterion
and a substantial natural variation of
‘‘normal’’ performance. Although it is
clear that the responsiveness of FCEs
must be studied, the question remains
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TABLE 1. Manual Material Handling Performances Before and After Treatment
Lifting Low (n=58) Lifting High (n=57) Carry Short (n=56) Pushing Static (n=44) Pulling Static (n=44)
Mean 1 (SD) 28.6 (15.1) 16.0 (6.5) 33.6 (16.6) 35.8 (10.4) 43.8 (13.7)
Mean 2 (SD) 31.2 (17.7) 16.0 (6.5) 36.7 (16.5) 38.7 (13.0) 46.1 (16.2)
Mean diﬀerence (SD) (kg)  2.6 (9.6)*  0.00 (2.6)  3.0 (11.1)*  2.9 (7.5)*  2.3 (9.8)
Range of diﬀerence (kg)  30 to 16  4 to 6  48 to 22  21 to 11  30 to 20
95% CI of diﬀerence (kg)  5.1 to  0.06  0.68 to 0.68  6.0 to  0.07  5.2 to  0.66  5.3 to 0.65
*Signiﬁcant diﬀerence at Pr0.05 (paired samples t test).
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Opioids use for non-cancer pain
remains a contentious topic. Despite
medical societies’ endorsement, de-
bate continues over their use for
chronic non-cancer pain. While
this is a topic beyond the scope of
this letter, we like to oﬀer some
critique to Markenson et al1 on their
study of the eﬃcacy of controlled-
release (CR) oxycodone for treatment
of osteoarthritic pain over a 90-day
period.
Tolerance is a major concern
with the long-term use of opioids.
Markenson et al were limited in
addressing this issue. They suggested
in this article that patients did not
become tolerant since dose remained
relatively low. The short follow-up
period and the small number of
patients that completed the entire
study (36 of 107) make conclusions
about whether or not tolerance was
developing speculative at most.
Furthermore, the method of data
analysis used in this study was intent
to treat (ITT) with the last observa-
tion carried forward (LOCF) of all
patients that received at least 1 dose
of drug. However, by carrying for-
ward the last observation, the data
may have marginalized the impact of
tolerance by integrating data from
patients that discontinued before tol-
erance could develop with data from
patients that continued until day 90.
Indeed, the report displays a discre-
pancy when completers of the study
are examined alone. Among comple-
ters the average pain decrease was not
signiﬁcant against placebo at day 90.
In addition, despite remarks of the
relatively low dose used during the
study, the average daily dose of
CR oxycodone did increase after
initial titration. No explanation is
oﬀered for the increase in average
dosing after a seemingly adequate
minimum of 15 days to titrate dosing.
Other studies investigating opioid
treatment for chronic non-cancer pain
have examined long-term outcomes
through use of open-label extensions.
However, the potential bias asso-
ciated with open-labels and the mi-
nority of patients electing to continue
through these extensions do not allow
conclusions regarding tolerance.2
Two studies examining opioid eﬃcacy
in chronic non-cancer pain have
indicated that pain intensity levels
began to rise after 4 weeks.3,4
Whether, as one of author suggests,
a 30-day period for titration is inade-
quate to achieve pain control or
whether tolerance developed is un-
certain.3 However, these trends stress
the need for stringent investigation
into the development of tolerance
with long-term opioid treatment of
non-cancer pain.
The study by Markenson’s et al
cannot support their conclusion. In
fact, we believe it creates confusion
among pain management providers
when it alludes to CR oxycodone
being a drug of choice for osteo-
arthritis when the evidence presented
is weak at best.
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